nctId,briefTitle,overallStatus,phase,studyType,leadSponsor,conditions,drug_raw,drug_normalized,intervention_type,arm_label,arm_type,role,is_candidate_drug,is_combo,outcome_label_mvp,outcome_confidence_mvp,has_resultsSection,primary_endpoint_met_final,outcome_label_final,confidence_final,evidence_source,primary_outcome_title,primary_outcome_timeframe,primary_outcome_pvalues,notes_ctgov,pubmed_pmids,notes_pubmed
NCT04471792,Creatine Use and Muscle Stretching in Peripheral Artery Disease,COMPLETED,PHASE2,INTERVENTIONAL,Florida State University,Peripheral Arterial Disease,Creatine monohydrate,creatine monohydrate,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Walking Distance,Baseline and after 4 weeks of intervention,p=0.38,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.38,,
NCT02807779,Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging,COMPLETED,PHASE4,INTERVENTIONAL,"University of California, San Francisco",Peripheral Artery Disease | Vascular Disease | Critical Limb Ischemia,Dexamethasone infusion,dexamethasone infusion,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Change in Percent Wall Volume (PWV),From Post-Operative Day One to 12 Months,p=0.22,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.22,,
NCT04610892,Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction,COMPLETED,PHASE2,INTERVENTIONAL,AstraZeneca,Coronary Heart Disease (CHD),MEDI6570,medi6570,BIOLOGICAL,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,"Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA) Imaging",From baseline to Day 253,"p=0.065, p=0.563, p=0.685","Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.065, p=0.563, p=0.685",,
NCT03743636,Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease,COMPLETED,PHASE3,INTERVENTIONAL,Northwestern University,Peripheral Artery Disease,Nicotinamide riboside,nicotinamide riboside,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Six-minute Walk Distance (NR Alone vs. Placebo),Baseline to 6-month follow-up,p=0.0775,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0775,,
NCT03743636,Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease,COMPLETED,PHASE3,INTERVENTIONAL,Northwestern University,Peripheral Artery Disease,Resveratrol,resveratrol,DRUG,,,OTHER,1,1,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Six-minute Walk Distance (NR Alone vs. Placebo),Baseline to 6-month follow-up,p=0.0775,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.0775,,
NCT03473223,Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome,COMPLETED,PHASE3,INTERVENTIONAL,CSL Behring,Acute Coronary Syndrome,Apolipoprotein A-I [human] (apoA-I),apolipoprotein a-i human apoa-i,BIOLOGICAL,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,"Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke)",From the time of randomization through 90 days,p=0.121,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.121,,
NCT03363165,Hepatocyte Growth Factor to Improve Functioning in PAD,COMPLETED,PHASE2,INTERVENTIONAL,Northwestern University,Peripheral Artery Disease,VM202,vm202,DRUG,,,OTHER,1,0,UNCLEAR,LOW,1,N,NEGATIVE,MED,CTGOV_STRUCTURED,Six-minute Walk Distance,Change from baseline to six-month follow-up in six-minute walk distance,p=0.7586,Structured CT.gov extraction from resultsSection.outcomeMeasuresModule.outcomeMeasures (PRIMARY). p=0.7586,,
